All News

Choices

SLE Treatment Landscape: Abundance or Overload?

Janet Pope, MD, MPH, FRCPC

Imagine a world where the multiple drugs in Phase 2 and 3 trials actually get approved, and we get access to them? I know you may be thinking that I am overly optimistic, but there are so many drugs in development in lupus that we may have true difficulty choosing what to use.

Read Article
RheumNow Podcast square

Moneyball Rheumatology (5.30.2025)

Jack Cush, MD

Dr. Jack Cush reviews the book/movie, "Moneyball" and a suggests moneyball strategy is needed to find next level responses for our patients.

Read Article
CPPDwrist.JPG

Genetic Link to CPPD

EurekAlert!

In a first-of-its-kind genome-wide association study (GWAS) researchers have discovered two genes, RNF144B and ENPP1, that cause calcium pyrophosphate deposition (CPPD) disease in Americans of European and African descent.

Read Article
Checklist survey

Contemporary lupus nephritis treatment

Janet Pope, MD, MPH, FRCPC

Outcomes in lupus nephritis are akin to the glass half full. Serial monotherapy is out, as the percentage who achieved a complete renal response was very low and some went to end stage kidney disease (ESKD). Solutions?

Read Article
SLE.organ_.jpg

2025 ACR Guideline for the Treatment of SLE

Jack Cush, MD

The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE. 

Read Article
pregnancy,embryo,fetal

IMPACT Study - Certolizumab Efficacy in APS Pregnancies

Jack Cush, MD

A pilot trial assessed the safety and value of tumour necrosis factor α inhibitor treatment with certolizumab in patients with high-risk pregnancies with antiphospholipid syndrome (APS).

Read Article
RheumNow Podcast square

Diagnosing Neuropsychiatric SLE (5.23.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com - including views on the vagus nerve, NPSLE and CAR-T mania.

Read Article
Turkish study of 1263 primary care referrals to rheumatology found 35.7% with inflammatory rheumatic Dz (IRD), 17.7% osteoarthritis, and 11.2% regional pain syndromes. Another German study showed low risk of IRD if CRP <5 https://t.co/v5qYb7c7jP https://t.co/iq4NfcC3cH https://t.co/RQan6rQi8a

Links:

Dr. John Cush RheumNow ( View Tweet)
Contemporary lupus nephritis treatment The Lupus 2025 congress brought together world SLE thought leaders. Outcomes in lupus nephritis are akin to the glass half full. Serial monotherapy is out, as the percentage who achieved a complete renal response was very low and some https://t.co/4LVPeDn6r4
Dr. John Cush RheumNow ( View Tweet)
Early RA or undiff. arthritis (UA) shows initial hi-dose steroids have significantly better earlier outcomes, but lower doses have fewer early side effects. IMPROVED used high dose GC (60 mg/d tapered to 7.5 mg in 7wks). tREACH used lower dose GC (15 mg/d tapered in 10 wks to https://t.co/TkrGPb6EBZ
Dr. John Cush RheumNow ( View Tweet)
2025 ACR Guideline for the Treatment of SLE The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE. https://t.co/2NFwTllLZa https://t.co/i5Q5UfE9v3

Links:

Dr. John Cush RheumNow ( View Tweet)
Moving Targets in Lupus and Lupus Trials In the 1990s, developing lupus treatments became a priority, but success was elusive for 20 years. Belimumab was approved by showing only small differences from placebo in trials with 867 patients globally. Its efficacy was confirmed by https://t.co/TekxzTJjwC
Dr. John Cush RheumNow ( View Tweet)
MMWR: 1994 the U.S. Vaccines for Children program has covered the cost of vaccines for US children. Since 1994 routine child vaccinations will have prevented ~508 million illness, 32 million hospitalizations, & 1,129,000 deaths,; direct savings of $540 billion & societal savings https://t.co/JCeSFmIgxV
Dr. John Cush RheumNow ( View Tweet)
Shifting the Management Paradigm for SLE and Lupus Nephritis The paradigm for treating patients with systemic lupus erythematosus (SLE) is rapidly shifting and our patients will surely benefit with improved outcomes. https://t.co/idxMBTyTwp https://t.co/unxmjVst3D

Links:

Dr. John Cush RheumNow ( View Tweet)
Turkish study of 1263 primary care referrals to rheumatology found 35.7% with inflammatory rheumatic Dz (IRD), 17.7% osteoarthritis, and 11.2% regional pain syndromes. Another German study showed low risk of IRD if CRP <5 https://t.co/v5qYb7c7jP https://t.co/iq4NfcC3cH https://t.co/6lkTMSBUqc

Links:

Dr. John Cush RheumNow ( View Tweet)
Why DORIS or LLDAS #remission 🤔 ⬇️mortality ⬇️damage ⬆️QoL Dr Nikpour at On Rheum Assoc Shows Remission > LLDAS no pred ✅ best @RheumNow https://t.co/tFcPrkd5Vd

Links:

Janet Pope Janetbirdope ( View Tweet)
Does ADDING an #immunesuppressive To #belimumab in #SLE give more benefit? ❎ NO #RWE from Spain suggests no added improvement adding IS to Belimumab Should you switch Rx then? 🤷‍♀️ @RheumNow #LUPUS2025 poster110 #ClinicalPearl https://t.co/C3ydArMx7x

Links:

Janet Pope Janetbirdope ( View Tweet)
Why follow antiDNA and complements in #lupus #nephritis #LN #LUPUS2025 panel said To detect flare ?to consider after 3 to 5 yrs of remission to taper Rx ?but not for early response to Rx Just info from the panel with my opinion salted in @RheumNow https://t.co/bFUfN0PsFF

Links:

Janet Pope Janetbirdope ( View Tweet)
deep thoughts in #lupus Is ‘better’ the enemy of #remission? Is a complete renal response <50% at the end of contemporary #triple #therapy Something to celebrate? ▶️Yes better than old #SoC but a bit sobering We need RCTs that radically change paradigm #LUPUS2025 @RheumNow

Janet Pope Janetbirdope ( View Tweet)

Who does worse with #SLE #nature vs #nurture South American #lupus #registries ⬆️ activity ⬆️damage ⬇️age ⬇️SES ⬆️SLE #antibodies #Gladel registry and others vs Europe Environment >genetics 🤔 #LUPUS2025 #45poster @RheumNow @gponsestel https://t.co/XjiXHAMuGm

Links:

Janet Pope Janetbirdope ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×